One day this company will get some decent coverage:
This is a big deal. FDA approval in Striate quickly followed the Striate comparator study....Remplir should be going to market in the US by 2024....and Striate will already be selling well as Bio HOorizons continues it as its leading biological in its sales thrust....
Ann: Orthocell commences nerve repair study, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $80.59M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.0¢ | $24.44K | 62.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 649 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |